TerminatedPhase 2NCT00422201

Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion

Studying OBSOLETE: Cushing syndrome

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: HRA Pharma
Principal Investigator: Lynnette K Nieman, M.D.
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Intervention: Mifepristone(drug)
Enrollment: 18 enrolled
Eligibility: 18-85 years · All sexes
Timeline: 2007 – 2012

Study locations (15)

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
CHU de Bordeaux Hopital Haut Leveque, Bordeaux, France
C.H.U Albert Michallon, Grenoble, France
C.H.U. de Bicetre, Le Kremlin-Bicêtre, France
CHRU de Lille, Lille, France
Hopital de la Timone, Marseille, France
AP-HP, Hopital Cochin Pavillon CORNIL, Paris, France
CHU de Toulouse, Toulouse, France
University of Wuerzburg, Wuerzbug, Germany
Universita Degli Studi, Naples, Italy
University of Turin, Orbassano, Italy
University of Padova, Padua, Italy
Internal Medicine Endocrinology, Eindhoven, Netherlands
University Hosiptal of Groningen, Groningen, Netherlands
Erasmus Medical Center, Rotterdam, Netherlands

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00422201 on ClinicalTrials.gov

Other trials for OBSOLETE: Cushing syndrome

Additional recruiting or active studies for the same condition.

See all trials for OBSOLETE: Cushing syndrome →

← Back to all trials